Detailseite
Projekt Druckansicht

Zielgerichtete Lyse von Tumorstammzellen vermittelt durch chimäre T-Zellrezeptoren.

Antragsteller Dr. Patrick Schmidt
Fachliche Zuordnung Hämatologie, Onkologie
Immunologie
Förderung Förderung von 2012 bis 2013
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 228600964
 
Erstellungsjahr 2014

Zusammenfassung der Projektergebnisse

The Cancer Stem Cell (CSC) hypothesis puts a, not necessarily rare, subpopulation of cells on the top of a tumor forming hierarchy, pointing to the importance of their destruction when aiming on a final cure. However, current studies targeting CSCs rather focus on the tumor initiating capacities of these cells than on their maintaining capacity in an established lesion. In this report an immunotherapeutic approach of targeting the minor CSC subfraction by exploiting the stem cell related wnt-pathway is described. It was found that a memory effect, provided by engineered T cells, is essential to keep the re-formation of CSCs from bulk tumor cells under control. Furthermore, the treatment setting is able to re-activate the host’s non engineered T cells against the majority of tumor cells, which leads to a long lasting tumor-free survival in the mouse model system. These findings implicate a leading role for immunotherapy when targeting the tumor stem cell fraction.

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung